# RADIAN: HCP commentary report

> 19 verified statements (5 from clinicians verified by NPI or staff page) from 8 commentary sources · 4 findings · updated Oct 29, 2026

## Report

- Trial: Phase Ib/II Non-randomized Non-comparative Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma
- NCT ID: NCT05784012
- Registry: https://clinicaltrials.gov/study/NCT05784012
- Sponsor: Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
- Phase: Phase 1/Phase 2
- Status: Active, not recruiting
- Drugs: dostarlimab
- Version: v1.0.0, edition 1
- Accepted: 2026-10-29
- Last checked: 2026-10-29
- Release hash: ea40f5342ca1298a408dc1c1f7d6ade13af902ac8e1e3961957489d7ae2fe8a7

## Counts

- HCP commentary sources screened: 29
- Sources cited by verified statements: 9
- Verified statements: 19
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 5
- Findings: 4
- People found in screened sources: 4
- Voices cited: 4
- Cited voices identity-verified: 2
- Organisational or shared accounts (not counted as people): 1

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

RADIAN asks whether adding niraparib and dostarlimab to definitive radiotherapy, with or without cisplatin, improves outcomes in locally advanced head and neck squamous cell carcinoma. Whether further evaluation will support routine adoption remains open. A LinkedIn speaker, described in the source as scientific coordinator of the trial’s sponsor, welcomes further evaluation in cisplatin-fit patients. A radiation oncologist raises radiotherapy-toxicity concerns in cisplatin-unfit patients. One X account’s practice-impact rating is unexplained. The sources reviewed for this edition place the trial’s main results at ESMO 2026.

## Open Medical Affairs question

What cohort-specific evidence would distinguish continued research from a justified practice-change assessment while addressing the reported harm?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. A speaker's principal concern is prolonged radiotherapy toxicity in cisplatin-unfit cohort B
- F2. A speaker's encouragement supports continued evaluation in cisplatin-fit cohort A
- F3. The standard-of-care impact rating is categorical but unexplained
- F4. Praise centers on academic evidence generation and the research effort

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 4 | 4 | 4 | 1 | none recorded | 3 |
| F2 | 4 | 6 | 6 | 2 | none recorded | 4 |
| F3 | 1 | 1 | 1 | 0 | none recorded | 2 |
| F4 | 2 | 2 | 2 | 2 | none recorded | 4 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 1 | 0 | 0 | 0 | 3 | 11 | 1 | 4 posts and articles | yes |
| F2 | 1 | 0 | 0 | 0 | 3 | 7 | 1 | 5 posts and articles, 1 registry | yes |
| F3 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 post or article | no |
| F4 | 2 | 0 | 0 | 0 | 0 | 3 | 1 | 2 posts and articles | no |

### Trial dimensions

- Primary endpoint: 1-year disease free survival: F1 (1 shared claims), F2 (2 shared claims)
- Secondary endpoints: F1 (1 shared claims)
- Population and setting: F1 (3 shared claims), F2 (3 shared claims), F4 (1 shared claims)
- The comparison: F1 (3 shared claims), F2 (2 shared claims)
- Safety and tolerability: F1 (2 shared claims)
- Design and conduct: F1 (1 shared claims), F2 (1 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F1. A speaker's principal concern is prolonged radiotherapy toxicity in cisplatin-unfit cohort B

An X thread addresses how radiotherapy safety and disease-free survival should be evaluated together in RADIAN.

Source: X thread, 2026-10-24.

### F3. The standard-of-care impact rating is categorical but unexplained

An X post addresses whether RADIAN could change standard treatment.

Source: X thread, 2026-10-25.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 4 | Titles free |
| Detailed analysis | 5 sections | Paid |
| Verified statements with short source quotes and links | 19 | Paid |
| Trial aspects mapped | 9 | Free |
| Sources with links | 9 | Counts free |
| Speaker attribution for cited voices | 4 | Paid |

## Trial aspects

9 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: 1-year disease free survival | discussed | 4 | 5 |
| Secondary endpoints | discussed | 1 | 4 |
| Population and setting | discussed | 6 | 6 |
| The comparison | discussed | 5 | 4 |
| Safety and tolerability | discussed | 2 | 4 |
| Design and conduct | discussed | 1 | 4 |
| Perceived standard-of-care impact | discussed | 1 | 1 |
| Academic independence and cooperative-group research value | discussed | 2 | 2 |
| PRIME: separate surgery-directed experience with niraparib and dostarlimab | discussed | 7 | 1 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 15 | 6 |
| YouTube | 6 | 1 |
| Bluesky threads | 4 | 0 |
| LinkedIn posts | 1 | 1 |
| Podcasts | 2 | 0 |
| X videos | 1 | 0 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2019-04-08 to 2026-10-27
- Cited window: 2025-11-19 to 2026-10-25
- Retrieved: 2026-10-28

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Phase Ib/II Non-randomized Non-comparative Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma
- Registry: NCT05784012 (https://clinicaltrials.gov/study/NCT05784012)
- Study IDs: TTCC-2022-01-RADIAN · 2024-516779-33-00
- Sponsor: Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
- Collaborators: GlaxoSmithKline, MFAR
- Design: Phase 1/Phase 2 · interventional, non randomized, parallel, phase1, phase2
- Status: Active, not recruiting
- Enrollment: 34 (actual)
- Start: 2023-11-13 (actual)
- Primary completion: 2027-03 (estimated)
- Primary endpoint: 1-year disease free survival (1 year after the start of the study treatment)
- Intervention: Dostarlimab (drug)
- Intervention: Niraparib (drug)
- Intervention: cisplatin plus radiotherapy (drug)
- Intervention: Niraparib (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 10 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits apply, so some matching discussion may be missing.
- The sources reviewed are not a representative sample of HCP opinion. Multiple closely overlapping posts by one author do not establish consensus or independent confirmation.
- Discussion using unnamed trial references, alternative wording or transcription variants may be missing. Many sources without explicit trial naming were not read, and one additional X discussion was not fully assessed for clinician views.
- No full RADIAN protocol or exact-trial results publication was available among the sources reviewed. Historical comparability, statistical uncertainty and detailed safety cannot be independently evaluated here.
- Exact product-label documents for dostarlimab and cisplatin plus radiotherapy were unavailable; this report draws no regulatory conclusion.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- PRIME comments concern a separate neoadjuvant, surgery-directed study. They cannot establish efficacy, safety or patient-selection rules for RADIAN's definitive-radiotherapy setting.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-29: current edition

Last checked for new commentary 2026-10-29. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (19 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (2 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/radian-nct05784012
- Agents: POST https://www.erudio.com/api/orders with {"report": "radian-nct05784012", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=radian-05784012

## Cite

Erudio Health. RADIAN (NCT05784012): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 29, 2026. https://www.erudio.com/reports/radian-nct05784012

## Machine access

- JSON: https://www.erudio.com/reports/radian-nct05784012.json
- Markdown: https://www.erudio.com/reports/radian-nct05784012.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "radian-05784012"}`